Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea
- Authors
- Kim, D.-H.; Oh, I.-Y.; Lee, H.-Y.; Kim, Y.-J.; Kim, H.-S.; Kim, C.-H.; Oh, B.-H.; Kim, K.-S.; Kim, D.-I.; Kim, Y.-D.; Ryu, K.-H.; Park, S.-H.; Baek, S.-H.; Shin, D.-G.; Shim, W.J.; Ahn, T.-H.; Oh, S.-K.; Lee, S.-H.; Lee, S.-Y.; Jeong, M.-H.; Chung, W.-S.; Jeong, J.-Y.; Choi, S.-Y.; Choi, S.-W.; Hyon, M.-S.
- Issue Date
- 2010
- Keywords
- Diabetes mellitus; Endothelium; Hypertension; Lacidipine
- Citation
- Korean Circulation Journal, v.40, no.12, pp.632 - 638
- Indexed
- SCOPUS
KCI
- Journal Title
- Korean Circulation Journal
- Volume
- 40
- Number
- 12
- Start Page
- 632
- End Page
- 638
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/118290
- DOI
- 10.4070/kcj.2010.40.12.632
- ISSN
- 1738-5520
- Abstract
- Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function. Copyright © 2010 The Korean Society of Cardiology.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.